Summary
Vertex Pharmaceuticals Inc. reported its first-quarter 2025 financial results, showing a slight increase in total revenues to $2.77 billion, up 3% year-over-year, primarily driven by the sustained performance of TRIKAFTA/KAFTRIO and the initial contributions from its new cystic fibrosis (CF) medicine, ALYFTREK. However, net income saw a significant decline of 41% to $646.3 million, compared to $1.1 billion in the prior year. This decrease was largely influenced by a substantial $379 million intangible asset impairment charge related to the discontinuation of the VX-264 clinical program for type 1 diabetes, and a decrease in acquired in-process research and development (AIPR&D) expenses. The company continues to invest heavily in research and development, with expenses rising 24% year-over-year, reflecting advancements across its diverse pipeline, including treatments for sickle cell disease (SCD), acute pain, and various rare diseases. The launch of JOURNAVX for acute pain has shown early traction with over 20,000 prescriptions written within its first two months. Despite the decrease in net income, Vertex maintains a strong liquidity position with over $11.3 billion in cash, cash equivalents, and marketable securities, supporting ongoing operations and strategic investments.
Financial Highlights
46 data points| Revenue | $2.77B |
| Cost of Revenue | $363.00M |
| Gross Profit | $2.41B |
| SG&A Expenses | $396.40M |
| Operating Expenses | $2.14B |
| Operating Income | $630.10M |
| Net Income | $646.30M |
| EPS (Basic) | $2.52 |
| EPS (Diluted) | $2.49 |
| Shares Outstanding (Basic) | 256.90M |
| Shares Outstanding (Diluted) | 259.50M |
Key Highlights
- 1Total revenues increased 3% year-over-year to $2.77 billion, driven by TRIKAFTA/KAFTRIO and ALYFTREK.
- 2Net income decreased 41% to $646.3 million, impacted by a $379 million intangible asset impairment charge for the VX-264 program.
- 3Research and development expenses increased 24% to $979.7 million, reflecting continued pipeline investment.
- 4Acquired in-process R&D expenses decreased significantly by 74% to $19.8 million.
- 5The company recorded a $379.0 million intangible asset impairment charge due to the discontinuation of the VX-264 clinical program for type 1 diabetes.
- 6Cash, cash equivalents, and marketable securities totaled $11.36 billion, indicating a strong liquidity position.
- 7The new acute pain medicine, JOURNAVX, generated over 20,000 prescriptions in its initial two months post-launch.